- PackSize
- 50ug/100ug
- Target
- CD258
- Reactivity
- Human
- Applications
- ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- Host Species
- Human
- Isotype
- IgG4-kappa
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 0.01M PBS, pH 7.4.
- Purification Process
- Protein A/G purified from cell culture supernatant.
- Purity
- >95% purity as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
- Clonality
- Monoclonal
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- Herpes virus entry mediator ligand, LIGHT, CD258, HVEM-L, HVEML, TNFSF14, Tumor necrosis factor ligand superfamily member 14, Herpesvirus entry mediator ligand
- Species
- --
- Gene ID-1
- O43557
- Uniprot
- --
- Background
- Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies.<br>• LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells., PMID:33606781<br/>• LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells., PMID:27835685<br/>• Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth., PMID:9765287<br/>• A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis., PMID:10318773<br/>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --